Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 28, 2015 11:57 PM ET


Company Overview of Tobira Therapeutics, Inc.

Company Overview

Tobira Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis, and human immunodeficiency virus (HIV-1). Its cenicriviroc product is an immunomodulator and dual inhibitor of CCR2 and CCR5 that is being evaluated for the treatment of non-alcoholic steatohepatitis, HIV-1, and others. The company was founded in 2006 and is based in South San Francisco, California.

701 Gateway boulevard

Suite 200

South San Francisco, CA 94080

United States

Founded in 2006

13 Employees



Key Executives for Tobira Therapeutics, Inc.

Chief Medical Officer
Age: 51
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2013.

Tobira Therapeutics, Inc. Key Developments

Tobira Therapeutics, Inc. Appoints Ian Clements as Vice President, Investor Relations and Corporate Communications

Tobira Therapeutics, Inc. announced the addition of Ian Clements, Ph.D., to the company's leadership team as vice president, investor relations and corporate communications. Dr. Clements brings over 20 years of industry experience to Tobira. Most recently he led investor relations and corporate communications at Avanir Pharmaceuticals, Inc. Previously he headed IR and corporate communications at Sequenom, Inc. Dr. Clements also held positions at the Trout Group and at Accelrys, Inc. Dr. Clements will join the company in July.

Tobira Therapeutics, Inc. Completes Patient Recruitment for CENTAUR Phase 2b Study of Cenicriviroc in NASH with Liver Fibrosis

Tobira Therapeutics, Inc. announced that it has completed recruitment for the Phase 2b CENTAUR study. CENTAUR is a global, double blind, placebo controlled, Phase 2b clinical trial evaluating the treatment effects of cenicriviroc (CVC) versus placebo in patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis at high risk of progressive disease. NASH is a severe form of non-alcoholic fatty liver disease. Patients with NASH and risk factors such as liver fibrosis and type 2 diabetes or metabolic syndrome are often at higher risk for progression to more advanced liver complications such as cirrhosis and liver cancer. Results of the one-year primary endpoint are anticipated to be announced in mid-2016. Tobira plans to submit further detail regarding study demographics for presentation at an upcoming scientific conference. The primary endpoint of the CENTAUR study is a two-point improvement in NAS (NAFLD Activity Score) without progression of fibrosis. The study will evaluate additional surrogate endpoints, including resolution of NASH with no concurrent worsening of fibrosis stage and measures of fibrosis improvement. These endpoints have been the focus of subgroup analyses in other NASH studies as well as industry and regulatory agency dialog and Tobira anticipates they may form the basis for future regulatory approvals of therapies for NASH with liver fibrosis.

Tobira Therapeutics, Inc., Annual General Meeting, Jul 09, 2015

Tobira Therapeutics, Inc., Annual General Meeting, Jul 09, 2015., at 08:00 Pacific Standard Time. Location: the offices of the company, 701 Gateway Blvd, Suite 300. Agenda: To elect the three director nominees named in the proxy statement accompanying this notice to serve as Class II directors for a three-year term expiring at the annual meeting of stockholders in 2018 and until their successors are duly elected and qualified; to ratify the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2015; to approve amendments to and the material terms of 2013 Equity Compensation Plan, including an increase in the number of shares reserved for issuance thereunder by 1,200,000 and, among other amendments, increases in or imposition of certain share limits under such plan; and to transact such other business as may properly come before the annual meeting or any adjournment thereof.

Similar Private Companies By Industry

Company Name Region
The Translational Genomics Research Institute United States
CPEX Pharmaceuticals, Inc. United States
Cryopharm Corporation United States
BioLegend, Inc. United States
GenPharm International, L.L.C. United States

Recent Private Companies Transactions

January 14, 2015
Regado Biosciences, Inc.
Private Placement
January 14, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tobira Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at